帕金森病认知障碍的诊断,评估和管理:来自修改后的Delphi过程的共识建议
Dana Pourzinal1, Deborah Brooks1, Deepa Sriram1
1UQ Centre for Clinical Research The University of Queensland Herston Queensland Australia.
Alzheimer's & dementia (Amsterdam, Netherlands)
|July 25, 2025
概括
在51个基于证据的建议上达成共识,用于诊断和管理帕金森病 (PD) 中的认知障碍. 这旨在规范护理并改善患者的治疗结果.
科学领域:
- 神经学 神经学
- 临床实践指南 临床实践指南
背景情况:
- 认知障碍在帕金森病 (PD) 中很常见.
- 临床管理的变化可能会推迟诊断和治疗.
- 协调临床实践对于最佳的患者护理至关重要.
研究的目的:
- 为了达成对PD认知障碍的最佳实践建议的共识.
- 建立诊断,评估和管理的指南.
- 提高认知障碍PD患者护理的一致性.
主要方法:
- 采用了经过修改的Delphi方法.
- 对29名澳大利亚PD专家提出了58项基于证据的建议.
- 使用5分利克尔特比例和书面反来衡量协议.
主要成果:
- 完成了51个基于证据的建议.
- 建议涵盖PD认知障碍的诊断,评估和管理.
- 达成了高水平的专家协议.
结论:
- 开发的建议为临床实践提供了一个框架.
- 这些指南旨在加强对PD认知障碍的护理.
- 标准化的建议将有助于改善患者的治疗结果.
相关概念视频
Parkinson's Disease: Treatment
381
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
381
Parkinson's Disease: Overview
710
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
710
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Dementia
166
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
166
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Psychosis: Goals of Pharmacotherapy
209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209


